OSE 703

Drug Profile

OSE 703

Alternative Names: Effi-3; OSE-703

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OSE Immunotherapeutics
  • Developer Memorial Sloan-Kettering Cancer Center; OSE Immunotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 26 Sep 2017 OSE Immunotherapeutics enters into an agreement with Selexis for clinical development of OSE 703
  • 26 Sep 2017 Preclinical trials in Non-small cell lung cancer in France (Parenteral)
  • 12 Jun 2017 OSE Immunotherapeutics and Memorial Sloan Kettering Cancer Center collaborate for development of research programme using OSE 703 for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top